Effectiveness and Safety of Cellbooster Glow in Healthy Subjects
NCT07929870, Not applicable, Not yet recruiting, Suisselle
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effectiveness and Safety of Cellbooster Glow in Healthy Subjects | ClinicalTrials.gov |
| NCT number | NCT07929870 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Suisselle | ClinicalTrials.gov |
| Conditions | Wrinkle Appearance, Skin Hydration in Healthy Volunteers, Skin Pigmentation, Skin Laxity, Dark Eye Circles (Periorbital Hyperpigmentation) | ClinicalTrials.gov |
| Interventions | Injectable | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from baseline recorded at visit 1 (Day -7 to Day 0) of epidermis hydration measured with Corneometer® at Day 42. | Day -7 to Day 0 and Day 42. | At each visit, five measurements will be taken on the right cheekbone, a few centimeters below the outer corner of the eye. The recorded value will be the average of the five measurements An improvement of epidermis hydration is defined as an increase higher than 2AU. | ClinicalTrials.gov |
| Secondary | Change from baseline of epidermis hydration measured with Corneometer® at Day 70. | Day 70 | ClinicalTrials.gov | |
| Secondary | Proportion of participants having an improvement with CBG treatment as assessed by the investigator at Day 42 and Day 70, using the GAIS. | Day 42 and Day 70 | An improvement is defined as participant having a score "very much improved", "much improved" or "improved" on the GAIS 5-grade scale: 1. Very much improved 2. Much improved 3. Improved 4. No change 5. Worse | ClinicalTrials.gov |
| Secondary | Degree of satisfaction of the injectors through the answers to a subjective evaluation questionnaire completed for each participant at Day 14. | Day 14 | For each question, the percentage of answers "satisfied" or "very satisfied" will be computed. 5-grade scale 1. :Strongly disagree 2. : Disagree 3. : Neither agree nor disagree 4. : Agree 5. : Strongly agree | ClinicalTrials.gov |
| Secondary | Degree of satisfaction of the participants through the answers to a subjective evaluation questionnaire at Day 42 and Day 70. | Day 42 and Day 70 | For each question, the percentage of participant satisfied, (percentages of answers "agree" or "strongly agree") will be computed. 5-grade scale: Strongly disagree / Disagree / Neither agree nor disagree / Agree / Strongly agree | ClinicalTrials.gov |
| Secondary | Change from baseline of skin elasticity measured with Cutometer® at Day 42 and Day 70. | Day 42 and Day 70 | ClinicalTrials.gov | |
| Secondary | Change from baseline of skin microcirculation measured with Laser Doppler at Day 42 and Day 70 | Day 42 and Day 70 | ClinicalTrials.gov | |
| Secondary | Change from baseline of skin wrinkles measured with fringe projection system at Day 42 and Day 70. | Day 42 and Day 70 | ClinicalTrials.gov | |
| Secondary | Change from baseline of skin roughness measured with fringe projection system at Day 42 and Day 70 | Day 42 and Day 70 | ClinicalTrials.gov | |
| Secondary | Illustration of the aesthetic effect with photos of the whole face (front face and profiles) with Colorface®. | Day 0, Day 42 and Day 70 | ClinicalTrials.gov | |
| Secondary | Change from baseline in the skin color and homogeneity | Day 0, Day 42 and Day 70 | Change from baseline in the skin color and homogeneity (L\*, a\*, b\*, ITA°,IWA, H76) measured with Colorface® at Day 0, Day 42 and Day 70. | ClinicalTrials.gov |
| Secondary | Change from baseline in the multi pigment spot measured with Colorface® | Day 0, Day 42 and Day 70 | Change from baseline in the multi pigment spot measured with Colorface® at Day 0, Day 42 and Day 70. | ClinicalTrials.gov |
| Secondary | Change from baseline in the contrast dark circle/ surrounding skin measured with Colorface® | Day 0, Day 42 and Day 70 | Change from baseline in contrast dark circle/ surrounding skin in deltaL\*, deltaa\*, deltab\*, deltaE76) measured with Colorface® at Day 0, Day 42 and Day 70. | ClinicalTrials.gov |
| Secondary | Change from baseline in the pigmented dark circle measured with Colorface® | Day 0, Day 42 and Day 70 | Change from baseline in the pigmented dark circle (L\*, a\*, b\*, H76) measured with Colorface® at Day 0, Day 42 and Day 70. | ClinicalTrials.gov |
| Secondary | Change from baseline in the global redness inflammation (haemoglobin evaluation) measured with Colorface® | Day 0, Day 42 and Day 70 | ClinicalTrials.gov | |
| Secondary | Change from baseline in gloss, and specular Gloss(GS)) measured with Colorface® | Day 0, Day 42 and Day 70. | Change from baseline in gloss (contrast gloss (GC) and specular Gloss(GS)) measured with Colorface® at Day 0, Day 42 and Day 70. | ClinicalTrials.gov |
| Secondary | Evaluation of Injection Site Reactions (ISRs) by the investigator on the face, immediately after each injection session (Day 0, Day 14 and Day 28) and at Day 42 and Day 70. | Day 0, Day 14, Day 28, Day 42 and Day 70. | ClinicalTrials.gov | |
| Secondary | Evaluation of Injection Site Reactions (ISRs) by the participant on the face during 2 weeks after each injection session. | Day 0, Day 14, Day 28 | Participant Injection Site Reactions (ISRs) will be tabulated by maximum severity, and duration, after each injection session. | ClinicalTrials.gov |
| Secondary | Collection of adverse events (AEs) and concomitant treatments during the study. | Day 0 to Day 70 | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)